Jazz Pharmaceuticals (JAZZ) Cash from Financing Activities (2010 - 2026)

Jazz Pharmaceuticals' Cash from Financing Activities history runs 17 years deep, the most recent figure standing at -$78.5 million for Q1 2026.

• In Q1 2026, Cash from Financing Activities rose 90.35% year-over-year to -$78.5 million; the TTM figure through Mar 2026 stood at -$138.4 million (up 81.21% YoY), while the FY2025 annual figure was -$873.4 million, down 4357.07% from the prior year.
• Cash from Financing Activities was -$78.5 million for Q1 2026 at Jazz Pharmaceuticals, down from $75.4 million in the prior quarter.
• In the past five years, Cash from Financing Activities ranged from a high of $246.4 million in Q3 2024 to a low of -$813.5 million in Q1 2025.
• Historically, Cash from Financing Activities has averaged -$103.9 million across 5 years, with a median of -$78.5 million in 2023.
• The sharpest annual moves came in 2022 and 2025: Cash from Financing Activities plunged 1581.78% in 2022, then surged 1011.66% in 2025.
• A 5-year view of Cash from Financing Activities shows it stood at $19.6 million in 2022, then slumped by 611.87% to -$100.3 million in 2023, then soared by 91.75% to -$8.3 million in 2024, then soared by 1011.66% to $75.4 million in 2025, then plunged by 204.06% to -$78.5 million in 2026.
• The last three Cash from Financing Activities figures came in at -$78.5 million (Q1 2026), $75.4 million (Q4 2025), and -$10.8 million (Q3 2025), per Business Quant data.